[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics director Barbara Ryan received 1,281 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. Each RSU converts to one share of common stock; the reported RSUs were granted in lieu of cash retainers and will vest one month from the grant date. Following the grant, Ms. Ryan beneficially owns 20,805 shares of common stock. The transaction price recorded for the RSUs is $13.86 per share (used for reporting purposes).

Positive

• Director compensation was converted to equity: 1,281 RSUs granted in lieu of cash retainers, aligning director pay with shareholder interests
• Near-term vesting: RSUs vest one month from grant date, resulting in a quick increase in reported beneficial ownership to 20,805 shares
• Transparent reporting: Transaction reported with specific share amount and per-share price of $13.86

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director equity grant increases insider ownership modestly; not material to operating performance.

The grant of 1,281 RSUs replaces cash retainers with equity, aligning director compensation with shareholder interests and modestly increasing Ms. Ryan's stake to 20,805 shares. The award vests quickly (one month), which means the reported RSUs will become shares in the near term. This is a common governance practice and, based on the data provided, appears immaterial to company valuation or near-term financials.

Corporate Governance Expert

TL;DR: Standard compensation disclosure showing equity-based pay for a director; governance-alignment signal but routine.

Granting RSUs in lieu of cash retainers is a standard approach to preserve cash and tie director incentives to stock performance. The one-month vesting period is short, indicating limited retention intent beyond immediate compensation replacement. The Form 4 reports beneficial ownership after the grant (20,805 shares), which improves transparency for shareholders reviewing insider holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		1,281	A	$13.86(1)	20,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MiNK Therapeutics (INKT) disclose about Barbara Ryan's transaction?

Ms. Ryan was granted 1,281 RSUs on 09/02/2025 as board and committee compensation in lieu of cash; these RSUs vest one month from the grant date.

How many shares does Barbara Ryan beneficially own after the reported transaction?

20,805 shares of MiNK Therapeutics common stock are reported as beneficially owned following the transaction.

What is the reporting price associated with the RSU grant?

$13.86 per share is the price shown in the Form 4 for the RSU transaction (used for reporting purposes).

Were the RSUs granted as cash or equity compensation?

The RSUs were granted in lieu of cash retainers for board and committee service.

When will the granted RSUs convert into shares?

The RSUs will vest one month from the grant date, at which point each RSU represents a contingent right to one share of common stock.